Stock Scorecard

Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $111.56 as of 11/20/2024 8:22:54 PM EST

Total Score

14 out of 30

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for LGND

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LGND

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LGND

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LGND

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LGND (54 out of 90)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 2

Latest News for for LGND

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Lifecore Biomedical ( NASDAQ:LFCR ) 10/17/2024 11:30:00 AM
invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology 10/15/2024 8:30:00 AM
Insider Move: Matthew E Korenberg Exercises Options, Realizing $704K At Ligand Pharmaceuticals - Ligand Pharmaceuticals ( NASDAQ:LGND ) 9/25/2024 3:01:00 PM
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Ligand Pharmaceuticals ( NASDAQ:LGND ) 9/19/2024 3:00:00 PM
Looking Into Ligand Pharmaceuticals's Recent Short Interest - Ligand Pharmaceuticals ( NASDAQ:LGND ) 8/16/2024 1:00:00 PM
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development 8/12/2024 8:30:00 PM
Agenus ( AGEN ) Q2 2024 Earnings Call Transcript 8/8/2024 8:15:00 PM
Bristol Myers' ( BMY ) Krazati Gets FDA Nod for Colorectal Cancer 6/24/2024 6:10:00 PM
Gilead Up as Twice-Yearly HIV Shot Prevents Infection - Gilead Sciences ( NASDAQ:GILD ) , ALX Oncology Holdings ( NASDAQ:ALXO ) 6/21/2024 7:28:00 PM
Gilead ( GILD ) Up as Twice-Yearly HIV Shot Prevents Infection 6/21/2024 1:17:00 PM

Financial Details for LGND

Company Overview
Ticker LGND
Company Name Ligand Pharmaceuticals Inc - Class B
Country USA
Description Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 111.56
Price 4 Years Ago 99.45
Last Day Price Updated 11/20/2024 8:22:54 PM EST
Last Day Volume 133,450
Average Daily Volume 121,549
52-Week High 129.90
52-Week Low 57.00
Last Price to 52 Week Low 95.72%

Valuation Measures
Trailing PE 44.86
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 19.15
Free Cash Flow Ratio 9.60
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 12.49
Total Cash Per Share 11.62
Book Value Per Share Most Recent Quarter 44.84
Price to Book Ratio 2.51
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 13.85
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 4

Share Statistics
Total Shares Outstanding 18,895,400
Market Capitalization 2,107,970,824
Institutional Ownership N/A

Dividends
Ex-Dividend Date 7/2/2010
Last Dividend Amount 15.00
Current Dividend Amount 0.46
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage -96.96%
3-Year Dividend Growth Rate Percentage -96.96%
5-Year Dividend Growth Rate Percentage -96.96%
All-Time Dividend Growth Rate Percentage -96.96%
Dividend Payout Ratio 0.00%

Income Statement
Quarterly Earnings Growth YOY 103.20%
Annual Earnings Growth 256.33%
Reported EPS 12 Trailing Months 2.49
Reported EPS Past Year 4.44
Reported EPS Prior Year 6.10
Net Income Twelve Trailing Months 45,244,000
Net Income Past Year 52,154,000
Net Income Prior Year -33,361,000
Quarterly Revenue Growth YOY 57.60%
5-Year Revenue Growth -8.31%
Operating Margin Twelve Trailing Months 0.21

Balance Sheet
Total Cash Most Recent Quarter 219,643,000
Total Cash Past Year 170,309,000
Total Cash Prior Year 211,870,000
Net Cash Position Most Recent Quarter 142,853,000
Net Cash Position Past Year 93,614,000
Long Term Debt Past Year 76,695,000
Long Term Debt Prior Year 76,695,000
Total Debt Most Recent Quarter 76,790,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.92
Total Stockholder Equity Past Year 700,913,000
Total Stockholder Equity Prior Year 597,485,000
Total Stockholder Equity Most Recent Quarter 841,178,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 75,115,000
Free Cash Flow Per Share Twelve Trailing Months 3.98
Free Cash Flow Past Year 46,056,000
Free Cash Flow Prior Year 119,927,000

Options
Put/Call Ratio 0.29
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 4.82
MACD Signal 3.74
20-Day Bollinger Lower Band 89.54
20-Day Bollinger Middle Band 104.08
20-Day Bollinger Upper Band 118.63
Beta 0.90
RSI 67.13
50-Day SMA 86.05
150-Day SMA 83.37
200-Day SMA 97.75

System
Modified 11/19/2024 5:24:51 AM EST